Ritesh Raichoudhury, MD
Nephrology · Flushing, NYNPI 1659304756
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,283 of the $4,742 with a category attached, or 69.2%. 19 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 31.6% of the total. Reporting peaked in 2019 at $1,992 and has fallen 93.8% since, to $123 in 2025.
Across 124 payments — averaging $38.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$850
- Vifor Pharma, Inc.$347
- Amgen$280
- Akebia Therapeutics Inc$258
- Aurinia Pharma U.S., Inc.$255
- plus $1K from 13 others
Across 6 payments — averaging $9005.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$32K
- Novartis$15K
- E.r. Squibb & Sons, L.L.C.$8K
What the payments were for
- Consulting fees$1,35028%
- Food & beverage$3,28369%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $1,497 |
| AstraZeneca(2 entities) | 32 | $850 |
| Vifor Pharma, Inc. | 16 | $347 |
| Amgen(2 entities) | 10 | $280 |
| Akebia Therapeutics Inc | 3 | $258 |
| Aurinia Pharma U.S., Inc. | 6 | $255 |
| Otsuka America Pharmaceutical, Inc. | 9 | $205 |
| OPKO Pharmaceuticals, LLC | 7 | $192 |
| Travere Therapeutics, Inc. | 7 | $175 |
| Fresenius USA Marketing, Inc. | 8 | $170 |
| Daiichi Sankyo Inc. | 6 | $148 |
| Bayer | 3 | $90 |
| Calliditas Therapeutics US Inc. | 3 | $63 |
| Cumberland Pharmaceuticals, Inc. | 5 | $58 |
| Johnson & Johnson | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| GSK | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,742 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $215 |
| Atorvastatin Calcium | 21 | $210 |
| Losartan Potassium | 14 | $195 |
| Furosemide | 17 | $91 |
| Amlodipine Besylate | 17 | $79 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Flushing
- Elizabeth LiangFlushing$53K
- Manish JotwaniFlushing$35K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.